Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

TSXV/PCLO stock hub

TSXV/PCLO has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

TSXV/PCLOis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

11M

TSX Venture Exchange

Market data

Live price

Current market quote for this ticker.

Current price

TSXV/PCLO

In the news

Latest news · TSXV/PCLO

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 11P50 15.6P75 25.4

Trailing P/En/a

P25 7.4P50 15.6P75 34.3

ROEn/a

P25 -121.5P50 -40.9P75 0.5

ROICn/a

P25 -72.5P50 -16P75 1.4

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All TSXV/PCLO market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

153

Groups with data

Currency

CAD

Showing 153 of 153 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Canada
Country code	CA
Enterprise value	CAD 29.4M
Exchange	TSX Venture Exchange
Financial currency	CAD
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	CA71716K1012
Last refreshed	2026-05-10
Market cap	CAD 11M
Price	CAD 0.06
Price currency	CAD
Sector	Healthcare
Sic	2834
Symbol	tsxv/PCLO
Website	https://www.pharmacielo.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-42.28%
EV Earnings	-6.31x
EV/Sales	16.77x
P/B ratio	-0.72x
P/S ratio	6.28x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-204.69%
EBITDA Margin	-149.03%
Gross margin	-17.66%
Gross Profit	CAD -309,336
Gross Profit Growth Q	170.02%
Net Income	CAD -4.7M
Net Income Growth Quarters	8%
Net Income Growth Years	2%
Pretax Margin	-265.71%
Profit Margin	-265.71%
ROCE	23.35

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	10.01%
Cagr3y	-34.96%
Cagr5y	-49.04%
EPS Growth Quarters	8
EPS Growth Years	0
Revenue Growth	-49.67x
Revenue Growth Q	-54.39x
Revenue Growth Years	0x
Revenue Growth3 Y	-30.9x
Revenue Growth5 Y	-7.98x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	CAD 8.6M
Cash	CAD 289,242
Current Assets	CAD 3.7M
Current Liabilities	CAD 23.9M
Debt	CAD 18.6M
Equity	CAD -15.4M
Interest Coverage	-1.49
Liabilities	CAD 23.9M
Long Term Assets	CAD 4.9M
Long Term Liabilities	CAD 0
Net Cash	CAD -18.4M
Net Cash By Market Cap	CAD -167
Tangible Book Value	CAD -15.4M
Tangible Book Value Per Share	CAD -0.08
WACC	8.77

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.15
Net Working Capital	CAD -1.9M
Quick ratio	0.04
Working Capital	CAD -20.3M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-9.4%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	10%
200-day SMA	0.07
3Y total return	-72.5%
50-day SMA	0.06
50-day SMA vs 200-day SMA	50under200
5Y total return	-96.56%
All Time High	11.5
All Time High Change	-99.52%
All Time High Date	2019-01-22
All Time Low	0.03
All Time Low Change	120%
All Time Low Date	2025-03-27
ATR	0.01
Beta	0.38
Beta1y	-4.45
Beta2y	-3.02
Ch YTD	22.22
High	0.06
High52	0.17
High52 Date	2026-01-05
High52ch	-66.67%
Low	0.05
Low52	0.04
Low52 Date	2026-04-21
Low52ch	57.14%
Ma50ch	-0.36%
Price vs 200-day SMA	-17.66%
RSI	52.15
RSI Monthly	35.54
RSI Weekly	45.13
Sharpe ratio	0.65x
Sortino ratio	1.22
Total Return	-9.4%
Tr YTD	22.22
Tr1m	22.22%
Tr1w	-8.33%
Tr3m	-31.25%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	CAD -3.6M
Operating margin	-204.7

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	169,110,817%
Net Borrowing	-5,237,400
Shares Insiders	15.5%
Shares Institutions	0.15%
Shares Out	200,137,631
Shares Qo Q	0%
Shares Yo Y	9.4%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	55,750.55x
Bv Per Share	-0.08
Ch1m	22.22
Ch1w	-8.33
Ch1y	10
Ch3m	-31.25
Ch3y	-72.5
Ch5y	-96.56
Ch6m	22.22
Change	0%
Change From Open	10
Close	0.06
Days Gap	-9.09
Depreciation Amortization	974,834
Dollar Volume	3,300
Earnings Date	2026-05-29
EBIT	CAD -3.6M
EBITDA	CAD -2.6M
EPS	CAD -0.02
F Score	2
Financing CF	-5,237,400
Fiscal Year End	March
Investing CF	6,688,657
Is Primary Listing	1
Last Earnings Date	2025-12-01
Last Report Date	2025-12-31
Last Split Date	2019-01-18
Last Split Type	Reverse
Ma150	0.06
Ma150ch	-12.42%
Ma20	0.05
Ma20ch	13.4%
Net CF	257,965
Next Earnings Date	2026-05-29
Open	0.05
Position In Range	100
Ppne	4,906,161
Price Date	2026-05-08
Relative Volume	1.12x
Revenue	1,751,510x
SBC By Revenue	-8.49x
Share Based Comp	-148,634
Tr6m	22.22%
Volume	60,000
Z Score	-38.42

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does TSXV/PCLO pay a dividend?

Capital-return profile for this ticker.

Performance

TSXV/PCLO stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns TSXV/PCLO?

Insider, institutional, and short-interest positioning.

Institutional ownership

+0.2%

Share of float held by funds and institutions

Insider ownership

+15.5%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+9.4%

Negative means the company is buying back shares.

Technical

TSXV/PCLO momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

52.1

Neutral momentum band

Price vs 200-day MA

-17.7%

50/200-day relationship not available

Beta (5Y)

0.38

Less volatile than the market

Sharpe ratio

0.65

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About TSXV/PCLO

Hub-level FAQ points readers to the deeper analysis pages.

What is the current tsxv/PCLO stock rating?

tsxv/PCLO is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full tsxv/PCLO analysis?

The full report lives at /stocks/tsxv/PCLO/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for tsxv/PCLO?

The latest report frames tsxv/PCLO around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the tsxv/PCLO page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.